Monday June 29, 3:00 pm Eastern Time
Company Press Release
SOURCE: Cypros Pharmaceutical Corporation
Cypros Pharmaceutical Corporation Presents at
Cruttenden Roth Growth Stock Conference June 29 - 30,
1998
NEW YORK, June 29 /PRNewswire/ -- Cypros Pharmaceutical Corporation (Amex: CYP - news)
employs the novel business model of building a specialty pharmaceutical business through product
acquisitions, and developing new cytoprotective drugs to treat a variety of ischemic conditions.
Ischemia (reduced blood flow) causes more deaths in developed countries than any other medical
condition and, currently, there are no approved drugs to treat it. Heart attack, stroke, head injury,
bypass surgery and various forms of anemia are ischemic disorders. Collectively, they result in over
700,000 deaths per year in the United States and incur over $200 billion in medical costs.
The Company's 10-person specialty pharmaceutical sales and marketing organization currently sells
three hospital-based products (Glofil, Inulin and Ethamolin(R). Glofil and Inulin are used to evaluate
kidney function and have been proven to be more accurate than the standard creatinine based tests.
The growth potential of these products is large (especially Glofil) and expected to be realized as the
Company builds its sales and marketing infrastructure. Ethamolin(R) is the only approved product for
the control of bleeding esophageal varices. The Company has recently acquired a proprietary,
sustained-release, drug delivery system (the ''Dimac System''). This novel, self-adhesive resin
delivers drugs topically. Two wound-care drugs (Sildimac and Medimac) have already been
incorporated within Dimac and are approved for marketing. The Company expects to launch these
products within the next six to nine months and to develop additional topical products using the
Dimac System.
The Company also has two cytoprotective drugs in late-stage clinical development for ischemic
disorders. Cordox(TM) is entering Phase III clinical trials for sickle cell anemia crisis and
Ceresine(TM) is being evaluated for a pivotal Phase III trial in head injury patients. Both
Cordox(TM) and Ceresine(TM) have broad, potential utility in ischemic disorders: including bypass
surgery, congestive heart failure and stroke; and, the patent portfolio for these drugs continues to
expand.
The Company plans to grow sales through its specialty pharmaceutical business in the near-term by
executing mergers and product acquisitions. Longer-term sales growth will be realized through the
launch of the Company's development-stage products, Cordox(TM) and Ceresine(TM).
SOURCE: Cypros Pharmaceutical Corporation
|
